Relapsed or Refractory Marginal Zone B-cell Lymphoma
1 clinical trials · Condition
◉ Watch Relapsed or Refractory Marginal Zone B-cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| 131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma (NCT01678404) | Korea Cancer Center Hospital | 2011-10-01 |
Track Relapsed or Refractory Marginal Zone B-cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.